August 2024 Advances in minimal residual disease monitoring in multiple myeloma – Clinical Laboratory Sciences 2023
August 2024 An automated workflow based on data independent acquisition for practical and high-throughput personalized assay development and MRD monitoring in MM patients – CCLM 2024
August 2024 M-protein diagnostics in multiple myeloma patients using ultra-sensitive targeted mass spectrometry and an off-the-shelf calibrator – CCLM 2024
August 2023 Reference Values to Assess Hemodilution and Warn of Potential False-Negative Minimal Residual Disease Results in Myeloma – Cancers 2021
August 2023 Clinical value of measurable residual disease testing for assessing depth, duration, and direction of response in multiple myeloma – Blood Adv. 2020
June 2023 IMWG consensus criteria for response and minimal residual disease assessment in Multiple Myeloma – Lancet Oncol. 2016
June 2023 Clinical Applications and Future Directions of Minimal Residual Disease Testing in Multiple Myeloma – Front Oncol. 2020
June 2023 Making clinical decisions based on measurable residual disease improves the outcome in Multiple Myeloma – J Hematol Oncol. 2021
June 2023 Minimal Residual Disease in Myeloma: Application for Clinical Care and New Drug Registration – Clin Cancer Res. 2021
